Pietro Rosa TBM Wins Rolls-Royce “Trusted to Deliver Excellence” Award 2018
8.7.2019 11:44:00 EEST | Business Wire | Press release
The 2019 Rolls-Royce Global Supply Chain Conference witnessed Pietro Rosa TBM being awarded the 2018 Trusted to Deliver Excellence award. This prestigious award is presented to suppliers who consistently demonstrate excellence in their work with Rolls-Royce. The awards ceremony took place on May 8th 2019 at the Rolls-Royce Supply Chain Conference held in Derby, United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190708005275/en/
4th from right: Mauro Fioretti - President and CEO Pietro Rosa Group. Rolls-Royce leadership team: Lee Fromson - EVP Compressors, Frazer McIntosh - Head of M.E. Civil Aerospace, Chris Chorlaton - President R-R Civil Aerospace, Alex Hislop – SME Compressors, Warwick Mathews - Procurement and Installations, Sebastian Resch - Ops Director Civil Aerospace, Garry Train – Manufacturing Exec Compressors (Photo: Business Wire)
Mauro Fioretti President and CEO of Pietro Rosa Group received the award on behalf of the company from Warrick Mattheus – Rolls-Royce EVP Procurement and Installations SCU and Sebastian Resch - Operations Director, Civil Aerospace.
The Trusted to Deliver Excellence award is representative of the fundamental collective mindset of the Rolls-Royce leadership team and workforce, capturing the very essence of a business that consistently drives forward to excel in customer satisfaction.
Pietro Rosa TBM has worked with Rolls-Royce for over 25 years on a variety of complex projects for Aero, Marine and Industrial applications, Most recently Pietro Rosa TBM has been supporting the first shipments of the Trent 1000 TEN KN kits destined to support Boeing and other airline customers. The Pietro Rosa TBM and Rolls-Royce teams have collaborated extremely well to achieve the desired goals.
Mauro Fioretti - President and CEO of Pietro Rosa Group commented:
“It is both a privilege and an honour to be awarded this mark of recognition by Rolls-Royce, we always feel proud to work with such a great team to a achieve a common goal. Stretch challenges are in our DNA, its what our company thrives on”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190708005275/en/
Contact information
Pietro Rosa TBM
Pietro Rosa Group Media
Clive Cunliffe
media@pietrorosacorporate.com
Or telephone +18606771376 (Ext 3310)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 13:17:00 EEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom